Navigating Between ADCs in NSCLC

Author(s):

The panel examines the characteristics of patients with non-small cell lung cancer (NSCLC) without actionable alterations who might be the best candidates for frontline treatment with either sacituzumab govitecan or datopotamab deruxtecan (Dato-DXd) and identifies the persisting unmet needs for this patient population.

EP: 1.Treatment Strategies for NSCLC with Non-Actionable Mutations

EP: 2.Role of Antibody-Drug Conjugates in NSCLC Treatment: Insights from EVOKE-02

EP: 3.Exploring the TROPION-Lung04 Study

EP: 4.Exploring Dato-DXd Combinations as First-Line Therapy for Advanced NSCLC

Now Viewing

EP: 5.Navigating Between ADCs in NSCLC

EP: 6.Advancing Treatment for EGFR-Mutant Advanced NSCLC: Lessons from FLAURA2

EP: 7.Osimertinib Monotherapy vs. Combination Therapy: Patient Selection in EGFR-Mutant Advanced NSCLC

EP: 8.MARIPOSA Study Insights

EP: 9.Optimizing Therapy Selection in EGFR Mutant NSCLC

EP: 10.ASCO 2024 Updates: Novel Approaches in NSCLC Therapy

EP: 11.Overview of TROP2 & Potential Role of TROP2-Directed ADCs in NSCLC

EP: 12.Key Takeaways from TROPION Trials: Implications for NSCLC Treatment Landscape

EP: 13.Targeting of HER3: Insights from HERTHENA-Lung01

EP: 14.Challenges and Learnings from EVOKE-01

EP: 15.Key ADC Studies at ASCO 2024

EP: 16.Mitigating Toxicities of Dato-DXd, Sacituzumab Govitecan, and HER3-DXd

EP: 17.Patient Selection and Sequencing of NSCLC ADCs

Which patients without actionable alterations might be most suitable for sacituzumabgovitecan versus Dato-DXd in the frontline setting?
What are the greatest remaining areas of unmet need in NSCLC without actionable mutations?
1. Is there any emerging research that may help to address these needs?
2. What are you most excited about in this space?